Immutep Ltd has released a press release.
Immutep receives A$1 million R&D Tax Incentive
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Immutep Webcast to discuss clinical data presented at SITC
- New Patents Granted in Japan and South Korea for Efti
- Late Breaking Abstract accepted for SITC Oral Presentation
- Independent DMC recommends to continue TACTI-003 as planned
- Abstracts accepted for Presentation at SITC 2022
Later from Immutep
- Immutep enters 2nd collaboration with Pfizer and Merck KGaA
- GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist
- Commercial Scale in Manufacturing of Efti Achieved
- Update on MBC trial design following successful FDA meeting
- TACTI-003 trial 50% enrolment milestone has been achieved
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep